PAXH's Q3 Loss Soars Amid R&D Push, Zero Revenue

TL;DR

**PAXH is a pre-revenue gamble, burning cash on R&D with a 'going concern' warning; avoid until a viable product and revenue stream emerge.**

AI Summary

PREAXIA HEALTH CARE PAYMENT SYSTEMS INC. (PAXH) reported no revenue for the three months ended August 31, 2025, consistent with the prior year. The company experienced a significant increase in net comprehensive loss, rising to $874,906 for the quarter ended August 31, 2025, from $4,627 in the same period of 2024. This substantial loss was primarily driven by a surge in operating expenses, which totaled $875,203, up from $4,627 in the prior year. Key expense increases included $391,263 in research and development, $387,500 in management and labor, and $65,000 in consulting. The company's financial position improved with total assets reaching $1,150,285 as of August 31, 2025, compared to zero on May 31, 2025, largely due to $130,285 in cash and $1,020,000 in prepaid expenses. Liabilities decreased from $2,341,169 to $722,963, primarily due to a reduction in related party loans from $1,627,421 to $100,438. The company's shareholders' equity shifted from a deficit of $2,341,169 to a positive $427,322, bolstered by $3,651,222 in stock subscriptions, including $1,643,397 for debt and $1,800,000 for services. Despite these capital injections, the company's accumulated deficit grew to $6,085,524, and management expressed substantial doubt about its ability to continue as a going concern without additional capital.

Why It Matters

For investors, PAXH's continued lack of revenue and escalating losses, despite significant capital injections, signals extreme risk. The shift from a shareholder deficit to positive equity is a technical improvement, but the underlying business remains in the development stage with no clear path to profitability. Employees face uncertainty given the 'going concern' warning, while customers are non-existent as products are still under development. In the competitive healthcare payment and personal financial management space, PAXH's inability to generate revenue puts it far behind established players, making its long-term viability highly questionable without a dramatic shift in strategy and execution.

Risk Assessment

Risk Level: high — The company reported zero revenue for the three months ended August 31, 2025, and incurred a net comprehensive loss of $874,906, a substantial increase from $4,627 in the prior year. Management explicitly stated 'substantial doubt about the Company's ability to continue as a going concern' due to a lack of significant cash, material assets, operations, or revenue to cover operating costs.

Analyst Insight

Investors should exercise extreme caution and consider avoiding PAXH stock. The company is in a pre-revenue development stage with significant losses and a 'going concern' warning. Monitor for concrete evidence of product launch, revenue generation, and a clear path to profitability before considering any investment.

Financial Highlights

debt To Equity

1.69

revenue

$0

operating Margin

N/A

total Assets

$1,150,285

total Debt

$722,963

net Income

$(874,906)

eps

N/A

gross Margin

N/A

cash Position

$130,285

revenue Growth

0.0%

Revenue Breakdown

Key Numbers

• $0 — Revenue (No revenue generated for the three months ended August 31, 2025 or 2024.)
• $(874,906) — Net Comprehensive Loss (Increased significantly from $(4,627) in Q3 2024, indicating rising operational costs without revenue.)
• $875,203 — Total Operating Expenses (A substantial increase from $4,627 in Q3 2024, driven by R&D, management, and consulting.)
• $391,263 — Research and Development Expenses (Incurred in Q3 2025, up from $0 in Q3 2024, reflecting investment in product development.)
• $427,322 — Total Shareholders' Equity (Improved from a deficit of $(2,341,169) on May 31, 2025, due to stock subscriptions.)
• $(6,085,524) — Accumulated Deficit (Increased from $(5,210,390) on May 31, 2025, highlighting historical losses.)
• $130,285 — Cash and Cash Equivalents (As of August 31, 2025, up from $0 on May 31, 2025, primarily from financing activities.)
• $3,651,222 — Stock Subscription (Total amount as of August 31, 2025, including $1,643,397 for debt and $1,800,000 for services.)
• $74,801 — Cash Used in Operating Activities (For the three months ended August 31, 2025, indicating ongoing cash burn from operations.)
• 19,767,698 — Common Stock Shares Outstanding (As of October 15, 2025, and consistent with August 31, 2025.)

Key Players & Entities

• PREAXIA HEALTH CARE PAYMENT SYSTEMS INC. (company) — registrant
• PAXH (company) — ticker symbol
• Securities and Exchange Commission (regulator) — filing oversight
• Zane Inc. CA (company) — wholly owned subsidiary created May 23, 2025
• Zane Inc. US (company) — wholly owned subsidiary created September 10, 2025
• Tiempo de Mexico Ltd. (company) — acquired by PreAxia on May 31, 2005
• PreAxia Health Care Payment Ltd. (company) — wholly owned subsidiary incorporated November 26, 2015
• $874,906 (dollar_amount) — net comprehensive loss for Q3 2025
• $4,627 (dollar_amount) — net comprehensive loss for Q3 2024
• $1,150,285 (dollar_amount) — total assets as of August 31, 2025

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: Management has expressed substantial doubt about the company's ability to continue as a going concern without additional capital. The company incurred a net comprehensive loss of $874,906 for the quarter ended August 31, 2025, and has an accumulated deficit of $6,085,524.
• Significant Increase in Operating Expenses [high — operational]: Operating expenses surged to $875,203 for the three months ended August 31, 2025, from $4,627 in the prior year. This increase was driven by substantial investments in research and development ($391,263) and management and labor ($387,500).
• Dependence on Capital Injections [high — financial]: The company's improved shareholders' equity of $427,322 is largely due to $3,651,222 in stock subscriptions, including $1,643,397 for debt and $1,800,000 for services. Future operations are contingent on continued access to such capital.
• Reduction in Liabilities [medium — financial]: Total liabilities decreased from $2,341,169 to $722,963, primarily due to a reduction in related party loans from $1,627,421 to $100,438. While this improves the balance sheet, the source and terms of these loan reductions are critical.
• High Consulting Expenses [medium — operational]: Consulting expenses amounted to $65,000 for the three months ended August 31, 2025, contributing to the overall increase in operating costs. The necessity and effectiveness of these services warrant scrutiny.

Industry Context

The health care payment systems industry is highly competitive and subject to significant regulatory oversight. Companies in this space typically generate revenue through transaction fees, subscription services, or software licensing. Recent trends include a push towards value-based care models, increased adoption of digital payment solutions, and evolving data security and privacy regulations.

Regulatory Implications

As a health care payment systems company, PAXH is subject to stringent regulations such as HIPAA for data privacy and security, and potentially other financial regulations depending on its specific services. Non-compliance can lead to significant fines and reputational damage.

What Investors Should Do

1. Monitor future capital raises and their terms.
2. Scrutinize the nature and necessity of R&D and consulting expenses.
3. Evaluate the company's path to revenue generation.
4. Assess the reduction in related party loans.

Key Dates

• 2025-08-31: End of third fiscal quarter — Reported $0 revenue, $874,906 net loss, and $1,150,285 in total assets, with $427,322 in shareholders' equity.
• 2025-05-31: End of second fiscal quarter — Reported $0 shareholders' equity (deficit of $2,341,169) and $0 in total assets.
• 2024-08-31: End of third fiscal quarter (prior year) — Reported $0 revenue and a net loss of $4,627, with total operating expenses of $4,627.

Glossary

Net Comprehensive Loss

The total loss incurred by a company during a period, including all revenues, expenses, gains, and losses that affect equity, excluding those resulting from investments by owners and distributions to owners. (Indicates the significant increase in operational costs and losses for PAXH in the current quarter.)

Accumulated Deficit

The cumulative net losses of a company that have not been offset by net income or other gains since its inception. (Shows the company's long-standing history of losses, contributing to the going concern uncertainty.)

Stock Subscriptions

Commitments from investors to purchase shares of a company's stock at a future date or upon specific conditions. (Represents a significant source of capital for PAXH, bolstering its equity but highlighting reliance on external funding.)

Prepaid Expenses

Expenses that have been paid in advance for goods or services to be received in the future. (A significant component of PAXH's assets, indicating future operational commitments or investments.)

Related Party Loans

Loans made between entities that are controlled by the same party or parties, or between an entity and its key management personnel. (The reduction in these loans is a key factor in the decrease of PAXH's liabilities.)

Going Concern

The assumption that a business will continue to operate for the foreseeable future, without the intention or need for liquidation or to otherwise cease trading. (Management's doubt about this status is a critical warning sign for investors regarding the company's viability.)

Year-Over-Year Comparison

PREAXIA HEALTH CARE PAYMENT SYSTEMS INC. (PAXH) shows a dramatic shift in its financial performance and position compared to the prior year's comparable period. While revenue remains at $0, the net comprehensive loss has ballooned from $4,627 to $874,906, driven by a massive increase in operating expenses, particularly in R&D and management. Total assets have transformed from $0 to $1,150,285, largely due to cash and prepaid expenses, while liabilities have decreased significantly. Shareholders' equity has moved from a substantial deficit to a positive $427,322, primarily funded by stock subscriptions, though the accumulated deficit continues to grow.

Key Financial Figures

• $0.001 — ection 12(g) of the Act: Common Stock, $0.001 par value (Title of class) Indicate
• $0 — s research and development expenses and $0 in the three months ended August 31, 20

Filing Documents

• paxh_10q-083125.htm (10-Q) — 410KB
• ex31x1.htm (EX-31.1) — 8KB
• ex32x1.htm (EX-32.1) — 4KB
• 0001079973-25-001628.txt ( ) — 2930KB
• paxh-20250831.xsd (EX-101.SCH) — 27KB
• paxh-20250831_cal.xml (EX-101.CAL) — 36KB
• paxh-20250831_def.xml (EX-101.DEF) — 95KB
• paxh-20250831_lab.xml (EX-101.LAB) — 235KB
• paxh-20250831_pre.xml (EX-101.PRE) — 199KB
• paxh_10q-083125_htm.xml (XML) — 303KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 1

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS 1

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 2

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 6

CONTROLS AND PROCEDURES

ITEM 4. CONTROLS AND PROCEDURES 6

– OTHER INFORMATION

PART II – OTHER INFORMATION 6

LEGAL PROCEEDINGS

ITEM 1. LEGAL PROCEEDINGS 6

RISK FACTORS

ITEM 1A. RISK FACTORS 6

CYBER SECURITY

ITEM 1C CYBER SECURITY 6

UNREGISTERED SALES OF EQUITY SECURITIES

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 6

DEFAULTS UPON SENIOR SECURITIES

ITEM 3. DEFAULTS UPON SENIOR SECURITIES 6

MINE SAFETY DISCLOSURES

ITEM 4. MINE SAFETY DISCLOSURES 6

OTHER INFORMATION

ITEM 5. OTHER INFORMATION 6

SIGNATURES

SIGNATURES 8 1 PART I - FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Article 210 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal recurring nature. Operating results for the three-month period ended August 31, 2025 are not necessarily indicative of the results that may be expected for the fiscal year ended May 31, 2026. For further information refer to the consolidated financial statements and footnotes thereto included in PreAxia's Annual Report on Form 10-K for the year ended May 31, 2025. Page Unaudited Condensed Consolidated Financial Statements Condensed Consolidated Balance Sheets as of August 31, 2025 (unaudited) and May 31, 2025 F-1 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended August 31, 2025 and 2024 F-2 Unaudited Condensed Consolidated Statements of Changes in Stockholders' Deficit for the three months ended August 31, 2025 and 2024 F-3 Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended August 31, 2025 and 2024 F-4 Notes to Unaudited Condensed Consolidated Financial Statements F-5 F-1 PreAxia Health Care Payment Systems Inc . Condensed Consolidated Balance Sheets As of August 31, 2025, and May 31, 2025 August 31, 2025 May 31, 2025 Assets (Unaudited) Current assets Cash and cash equivalents $ 130,285 $ — Prepaid expense 360,000 — Current assets 490,285 — Prepaid expense long-term 660,000 —

View Full Filing

View this 10-Q filing on SEC EDGAR